Frost & Sullivan Recognizes Selventa's Proprietary Systems Diagnostics Technology Platform
MOUNTAIN VIEW, Calif., May 13, 2013 /PRNewswire via COMTEX/ -- Based on its recent analysis of the systems diagnostics market, Frost & Sullivan recognizes Selventa with the 2013 North America Frost & Sullivan Award for Technology Leadership. Selventa stands out in the personalized diagnostics field with its proprietary Systems Diagnostics (SysDx(TM)) technology platform. SysDx(TM) tests make the most of the convergence of a broad range of complex, biological, molecular information to generate a clinically relevant report for physicians, patients, and researchers. This thorough personalized diagnostics approach lends strong validation, support and reliability to SysDx's reports.
"Selventa's technology can categorize patient subtypes by identifying the mechanistic biological drivers of disease, which is critical in clinical trials and clinical diagnosis," said Frost & Sullivan Sr Research Analyst Cecilia Van Cauwenberghe. "Selventa developed a stratified medicine approach by creating molecular footprints derived from individual's omics-based data to identify differentially expressed genes. This approach allows the SysDx to measure the signaling strength of the therapeutics' target in each individual's biological profile."
Diseases are characterized according to their phenotype, usually avoiding sub-categories related to specific mechanisms or genotypes--both important contributors to the phenotype. The most prominent reasons for the failure of clinical trials are either unmet pharmacology requirements or deficiencies in the mechanism targeted by the investigational agent. Indeed, the molecular drivers for most chronic diseases, including asthma, diabetes, Parkinson's and Alzheimer's diseases, as well as most cancers, demonstrate a variety of complexities beyond genomic variations.
Personalized medicine takes into account the myriad of interrelated, biochemical pathways involved in the evolution of the disease to create an optimal treatment solution. However, despite the significant strides taken by personalized medicine, especially in oncology, labs continue to underutilize routine testing procedures in the investigation of new agents in clinical trials.
The next-generation approach, proposed by Selventa through its SysDx(TM), enables the integration of new knowledge about a specific disease by consolidating and cross-referencing existing biomedical literature. The company has developed internal learning cycles by accruing insights from customers. This will help refine biomarker patterns to reveal enhanced therapeutics around the investigational agent.
"Selventa's knowledgebase, a collection of curated data characterizing over 2,200 different processes from a variety of sources, allows early identification of the disease-driving mechanisms," noted Van Cauwenberghe. "It is leading the development of predictive diagnostics in multi-factorial disease areas, including autoimmune and infectious diseases, and oncology."
The technology has already crossed important milestones in the field of breast cancer, rheumatoid arthritis, and inflammatory bowel disease. Its success has prompted the company to pump 13 percent of its revenues back into R&D.
Selventa also fosters strong relationships with pharmaceutical and biotechnology companies, diagnostic services companies, clinical research organizations, as well as academic- and government-affiliated clinical organizations.
Each year, Frost & Sullivan presents this award to the company that demonstrated excellence in technology leadership within its industry by excelling in all stages of the technology life cycle--incubation, adaptation, take up, and maturity--to ensure a continuous flow of improvements. By innovating leading-edge concepts, the company has pioneered client applications.
Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.
Selventa is pioneering the development of Systems Diagnostics (SysDx(TM)). This novel approach to diagnostic development harnesses a comprehensive range of complex, biological information (genomic, epigenomic, transcriptomic, proteomic, metabolomic, electronic medial records) to generate a clinically relevant dashboard that physicians, patients and researchers can use to make an optimal treatment decision or stratify patient populations.
SysDx tests are enabled by Selventa's "Big Data" analytics engine that integrates, processes, and analyzes the molecular information from thousands of patients to identify biomarkers linked to disease-driving mechanisms. SysDx tests are differentiated by their ability to capture a holistic picture of a patient's disease and drug-response profile. This is in contrast to MDx tests that are limited by their focus on a particular class of biological analytes (e.g. genomics-only tests). This superior predictive and prognostic value is required in the diagnosis of complex multi-factorial diseases such as autoimmune disease and cancer.For more information, visit www.selventa.com
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
-- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
-- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact Us: Start the discussion
Join Us: Join our community
Subscribe: Newsletter on "the next big thing"
Register: Gain access to visionary innovation
Mireya EspinozaP: 210. 247.3870F: 210.348.1003E: firstname.lastname@example.org
For more information, please contact:Diane H. Song, Ph.D., 617-547-5421 email@example.com
Constantine TheodoropulosBase Pair Groupconstantine@basepairgroup.comwww.basepairgroup.com
SOURCE Frost & Sullivan